Treatment of dental implant disease

Not Applicable

• Conditions: Periodontal disease, not otherwise specified; Z96.5

• Registration Number: RBR-268y2t4
• Lead Sponsor: niversidade do Estado do Rio de Janeiro

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-06-15
• Study Start: 2022-07-21
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Data analysis completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Included patients must have gingival bleeding around the implant, bone loss around the implant and the implant must have been in masticatory function for more than 01 year, patient of both sexes aged between 18 and 80 years, non-smokers, not using of systemic medication and patients should not be pregnant or lactating.

Exclusion Criteria

Excluded patients must not present: gingival bleeding around the implant, bone loss around the implant and the implant must not have been in mastication for more than 01 year, aged below 18 years or above 80 years, smokers, with use of systemic medication and pregnant and lactating patients, history of alcohol or drug abuse; diagnoses of cardiac, renal, gastrointestinal, hepatic, pulmonary, neurological, psychiatric, hematological or metabolic pathologies.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Peri-implant therapy with surgical access for scaling with or without the use of photodynamic therapy and 0.2% toluidine blue reagent resulted in similar improvement in clinical parameters in both groups. Bone levels remained stable after one year of treatment in both groups. Interleukin 6 and Osteocalcin levels were significantly reduced in the test and control groups after 1 year of treatment. In the test group there was a significant reduction in Leptin.